Great Elm Capital posts $0.32 GAAP NII, missing estimates by $0.03 Great Elm Capital reported Q2 GAAP Net Investment Income of $0.32, falling short of estimates by $0.03. The company's Total Investment Income was $10.89M, a 23.7% year-over-year decline, and missed exp
Regional declines led by South Korea's KOSPI offset gains in Australian equities as semiconductor stocks weighed on sentiment. Asian equities declined on Thursday, reversing Wall Street’s recent gains as a selloff in chipmakers pressured markets. South Korea’s KOSPI fell s
The plant-based meat company reported Q2 2026 revenue of $68.8 million, exceeding its $60M-$65M guidance range. Beyond Meat projected Q3 2026 net revenues of $60 million to $65 million, aligning with its strategic focus on Europe, Canada, and the Beyond Immerse platform. T
The newly spun-off aerospace unit resets guidance after supply chain challenges slowed recent output expansion. Honeywell Aerospace projected 4% to 5% organic sales growth for 2026, revising its outlook following supply constraints that tempered prior double-digit output g
The analytics firm reported Q2 revenue of $101 million and annual recurring revenue of $410 million, up 22% year-over-year. Amplitude projected FY2026 revenue between $407.2 million and $411.2 million, targeting a long-term operating margin above 20%. The guidance follows
CACI International reports stronger-than-expected Q4 earnings and revenue growth, with backlog increasing to $32.0 billion. CACI International posted Q4 non-GAAP earnings per share of $8.91, surpassing estimates by $1.68. Revenue reached $2.71 billion, up 17.8% year-over-y
Investors sold off major tech shares after SpaceX revealed a sixfold increase in Q2 capital expenditure to $18 billion. U.S. equities retreated Wednesday as concerns over AI spending weighed on tech stocks. The Nasdaq fell sharply, led by declines in SpaceX, Google, and Mi
Hennessy Advisors reports $0.25 GAAP EPS for Q2 as net income drops 6% due to early debt repayment. Hennessy Advisors posted Q2 GAAP earnings per share of $0.25 on revenue of $8.4 million. Net income declined 6% to $2.0 million, driven by the early redemption of debt.
The biotech firm expects topline results soon for its menopause treatment ABCL635 after completing enrollment in the trial. AbCellera announced $110M in upfront payments from new T-cell engager (TCE) collaborations, bolstering its cash position. The funds follow recent par
NLCP reports $0.47 FFO in line with expectations but revenue misses by $0.16M amid a 6.4% year-over-year decline. NewLake Capital Partners posted second-quarter funds from operations of $0.47 per share, matching analyst estimates. Revenue reached $12.1 million, missing exp
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.